SCYNEXIS soars on interim results of Phase 3 study of fungal treatment
SCYNEXIS Inc (NASDAQ:SCYX) rallied Thursday after announcing positive results from the first interim analysis of a Phase 3 open-label study.
The biotech said in a statement that its oral ibrexafungerp salvage treatment of hard-to-treat mucocutaneous and invasive fungal infections showed clinical benefits in 17 out of 20 patients.
The stock of the Jersey City, New Jersey company surged 69% to $1.22 in Thursday’s Nasdaq trading.
READ: Scynexis unveils favorable Phase 2b trials for yeast infection drug
“The positive results of this first interim analysis met all of our goals,” said Dr Marco Taglietti, CEO of SCYNEXIS.
Eleven patients achieving a complete or partial response and six patients a stable disease response, according to SCYNEXIS. Only two patients did not respond to ibrexafungerp treatment and the outcome for one patient was considered indeterminate.
Salvage therapy is applied after a patient fails to respond to standard therapy. In an open-label trial, both researchers and participants know what is being administered. Mucocutaneous junctions are found in areas such as the lips and nostrils.
The 20 patients evaluated in the interim analysis suffered from a variety of severe conditions, including esophageal candidiasis, intra-abdominal abscesses and oropharyngeal candidiasis.
The most common fungal species were Candida glabrata and Candida krusei, two highly resistant organisms, according to the company. The ibrexafungerp treatment ranged from seven to 90 days, with a mean duration of 36.4 days.
Contact Dennis Fitzgerald at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/213754/scynexis-soars-on-interim-results-of-phase-3-study-of-fungal-treatment-213754.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.
| Online: | |
| Visits: | 1,608,223,422 |
| Stories: | 8,163,964 |
Whistler Blowers, Insiders
